We are disappointed to see Novo Nordisk management misleading the public.
In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to
andrewdudum
3,402 posts
- All leaders & CEOs should use their platform today to call for an immediate cease fire. I ask us to find nuance, and share our voice to help save innocent lives.
- Today we announced $hims raised $1B, our largest raise yet, more than double what we set out for, thanks to strong demand from a wide range of leading investors. The offering was designed to accelerate long-term value creation and minimize shareholder dilution. More than just a
- The last few days have been a disheartening reflection of just how divisive a time we live in. I’d like to clarify a few things because my words have been misconstrued by some.
- At the core of $hims is a simple yet powerful idea: we use precision medicine to personalize the delivery of existing, clinically studied medications. We are not bypassing the regulatory process or creating new drugs. We focus on delivering better care through personalization.
- We’re exceeding our own high expectations at $HIMS. We announced today we’re increasing our outlook for the year, and now expect to achieve $1.2-1.23 billion in revenue and $120-135 million in Adjusted EBITDA in 2024, blowing by our previous 2025 targets. Personalized products
- Replying to @AndrewDudumAs a father whose children are both the descendants of Palestinian refugees who fled the Nakba in 1948, and the descendants of Holocaust survivors from Poland, as I have previously shared, I have a personal appreciation for the different perspectives people have which I live with
- Today we announce a strategic investment in $GRAL — the most advanced Multi-Cancer Early Detection (MCED) test on the market. When I was 12, my father was diagnosed with stage 4 colon cancer. He was 38 at the time, about the same age as I am today. Since hearing about early
- Some of the most comprehensive work I see on $HIMS is coming from our retail investor community. Apart from our internal teams and the millions of customers on our platform, no one is more passionate about this company and how we are pushing the healthcare industry forward. This
- Q3 results are in and here are the highlights: - We’re growing fast and efficient. Revenue is up 49% year over year. Adjusted EBITDA is up 53%. Increasing confidence we can meet and surpass 2030 targets of $6.5B and $1.3B in Adj. EBITDA. - Growth is becoming more diversified.
- What launches tomorrow took many years to perfect. From the industrial design of the machines to the safety procedures delivering consistency and quality. Tomorrow’s a small glimpse into the future of what we’re building. What I believe is one aspect of the future of
- When I met @dheerja, I was immediately struck by how clearly she sees the role technology plays in reshaping consumer behavior — and how to build for it. At Robinhood, she led Robinhood Gold, a membership product that fundamentally changed how people access financial services and






